The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine

References

• Lipton RB , Stewart WF. Migraine in the United States: a review of epidemiology and health care use. Neurology. 2002;58:885–894.
   PubMed Web of Science ®Google Scholar
• Stovner LJ , Hagen K , Jensen R , et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2007;27:193–210.
   PubMed Web of Science ®Google Scholar
• Headache Classification Subcommittee of the International Headache Society . The international classification of headache disorders. Cephalalgia. 2004;24(Suppl 1):9–160.
   PubMed Web of Science ®Google Scholar
• Murray CJL , Vos T , Lozano R , et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2197–2223.
   PubMed Web of Science ®Google Scholar
• Steiner TJ , Stovner LJ , Vos T. GBD 2015: migraine is the third cause of disability in under 50s. J Headache Pain. 2016;17(1):104.
   PubMed Web of Science ®Google Scholar
• Linde M , Gustavsson A , Stovner LJ , et al. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol. 2012;19:703–e43.
   PubMed Web of Science ®Google Scholar
• CoLucid Pharmaceuticals Announces Achievement of Both Primary and Key Secondary Endpoints in the SAMURAI Phase 3 Pivotal Trial of Lasmiditan in Migraine [Internet] . CoLucid Pharmaceuticals, Inc [ updated 2016 Sep 06; cited 2017 July 19]. Available from: https://globenewswire.com/news-release/2016/09/06/869611/0/en/CoLucid-Pharmaceuticals-Announces-Achievement-of-Both-Primary-and-Key-Secondary-Endpoints-in-the-SAMURAI-Phase-3-Pivotal-Trial-of-Lasmiditan-in-Migraine.html.
   Google Scholar
• Speck V , Maihöfner C. Migräne - Bewährtes und aktuelle Entwicklungen. [Migraine – established concepts and new developments]. Fortschr Neurol Psychiatr. 2013;81: 308–323. German.
   PubMed Web of Science ®Google Scholar
• Lampl C , Voelker M , Diener HC . Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms. J Neurol. 2007;254:705–712.
   PubMed Web of Science ®Google Scholar
• Neeb L , Reuter U . Lasmiditan for acute migraine treatment. Future Neurol. 2013;8(6):631–638.
   Google Scholar
• Rizzoli PB . Emerging therapeutic options for acute migraine: focus on the potential of lasmiditan. Neuropsychiatr Dis Treat. 2014;10:547–552.
   PubMed Web of Science ®Google Scholar
• Ferrari MD , Roon KI , Lipton RB , et al. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001;358:1668–1675.
   PubMed Web of Science ®Google Scholar
• Reuter U , Israel H , Neeb L . The pharmacological profile and clinical prospects of the oral 5-HT1F receptor agonist lasmiditan in the acute treatment of migraine. Ther Adv Neurol Disord. 2015;8(1):46–54.
   PubMed Web of Science ®Google Scholar
• Cameron C , Shannon K , Shu-Ching H , et al. Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache. 2015;55:221–235.
   PubMed Web of Science ®Google Scholar
• Magis D , Schoenen J . Treatment of migraine: update on new therapies. Curr Opin Neurol. 2011;24:203–210.
   PubMed Web of Science ®Google Scholar
• Pierce M , Marbury T , O’Neill C , et al. Zelrixtm: a novel transdermal formulation of sumatriptan. Headache. 2009;49(6):817–825.
   PubMed Web of Science ®Google Scholar
• O’Connor P , Gladstone P . Oral sumatriptan-associated transmural myocardial infarction. Neurology. 1995;45(12):2274–2276.
   PubMed Web of Science ®Google Scholar
• Jayamaha JEL , Street MK . Fatal cerebellar infarction in a migraine sufferer whilst receiving sumatriptan. Intensive Care Med. 1995;21(1):82–83.
   PubMed Web of Science ®Google Scholar
• Abbrescia VD , Pearlstein L , Kotler M . Sumatriptan-associated myocardial infarction: report of case with attention to potential risk factors. J Am Osteopat Assoc. 1997;97(3):162–164.
   PubMedGoogle Scholar
• Bally M , Dendukuri N , Rich B , et al. Risk of acute myocardial infarction with NSAIDs in real world use : bayesian meta-analysis of individual patient data. Bmj. 2017;357:j1909.
   PubMed Web of Science ®Google Scholar
• Gallagher RM , Cutrer FM . Migraine: diagnosis, management, and new treatment options. Am J Manag Care. 2002;8:58–73.
   Web of Science ®Google Scholar
• Lipton RB , Buse DC , Serrano D , et al. Examination of unmet treatment needs among persons with episodic migraine: results of the American migraine prevalence and prevention (AMPP) study. Headache. 2013;53(8):1300–1311.
   PubMed Web of Science ®Google Scholar
• Reuter U . Anti-CGRP antibodies: a new approach to migraine prevention. Lancet Neurol. 2014;13(9):857–859.
   PubMed Web of Science ®Google Scholar
• Diener HC , Barbanti P , Dahlöf C , et al. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia. 2011;31(5):573–584-.
   PubMed Web of Science ®Google Scholar
• Ho TW , Ferrari MD , Dodick DW , et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008;372:2115–2123.
   PubMed Web of Science ®Google Scholar
• Stovner LJ , Tronvik E , Hagen K . New drugs for migraine. J Headache Pain. 2009;10:395–406.
   PubMed Web of Science ®Google Scholar
• Voss T , Lipton RB , Dodick DW , et al. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia. 2016;36(9):887–898.
   PubMed Web of Science ®Google Scholar
• Barbanti P , Aurilia C , Egeo G , et al. Serotonin receptor targeted therapy for migraine treatment: an overview of drugs in phase I and II clinical development. Expert Opin Investig Drugs. 2017;26(3):1–9.
   PubMed Web of Science ®Google Scholar
• Martelletti P . Acute treatment of migraine: quo vadis? Expert Opin Pharmactother. 2017. DOI:10.1080/14656566.2017.1329821
   Google Scholar
• Lucaites VL , Krushinski KH , Schaus JM , et al. [3H]LY334370, a novel radioligand for the 5-HT1F receptor. II. Autoradiographic localization in rat, guinea pig, monkey and human brain arch. Pharmacol. 2005;371(3):178–184.
   Web of Science ®Google Scholar
• Johnson KW , Schaus JM , Durkin MM . 5-HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs. Neuroreport. 1997;8:2237–2240.
   PubMed Web of Science ®Google Scholar
• Cohen Z , Bouchelet I , Olivier A , et al. Multiple microvascular and astroglial 5-hydroxytryptamine receptor subtypes in human brain: molecular and pharmacologic characterization. J Cereb Blood Flow Metab. 1999;19(8):908–917.
   PubMed Web of Science ®Google Scholar
• Goldstein DJ , Roon KI , Offen WW , et al. Selective seratonin 1F (5-HT 1F) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet. 2011;358:1230–1234.
   Web of Science ®Google Scholar
• Reuter U , Neeb L . Lasmiditan hydrochloride. Drugs of the Future. 2012;37(10):709–716.
   Web of Science ®Google Scholar
• Nelson DL , Phebus LA , Johnson KW , et al. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia. 2010;30(10):1159–1169.
   PubMed Web of Science ®Google Scholar
• Färkkilä M , Diener HC , Géraud G , et al. Efficacy and tolerability of lasmiditan, an oral 5-HT 1F receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol. 2012;11(5):405–413.
   PubMed Web of Science ®Google Scholar
• Capi M , De Andrés F , Lionetto L , et al. Lasmiditan for the treatment of migraine. Expert Opin Investig Drugs. 2017;26(2):227–234.
   PubMed Web of Science ®Google Scholar
• Liefaard L , Drenth HJ , Pilgrim AJ , et al. Prediction of therapeutically effective dose of COL-144 based on relationship between plasma concentrations and headache response (poster). Cephalalgia. 2009;29:24.
   Web of Science ®Google Scholar
• Ferrari MD , Färkkila M , Reuter U , et al. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan - a randomised proof-of-concept trial. Cephalalgia. 2010;30(10):1170–1178.
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen PC , Olesen J . The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials. J Headache Pain. 2012;13(4):271–275.
   PubMed Web of Science ®Google Scholar
• CoLucid Pharmaceuticals Announces Achievement of Secondary Endpoints in SAMURAI [Internet] . CoLucid Pharamceuticals, Inc [ updated 2016 Sep 17; cited 2017 July 19]. Available from: https://globenewswire.com/news-release/2016/09/17/872599/0/en/CoLucid-Pharmaceuticals-Announces-Achievement-of-Secondary-Endpoints-in-SAMURAI.html.
   Google Scholar
• Lionetto L , Negro A , Palmisani S , et al. Emerging treatment for chronic migraine and refractory chronic migraine. Expert Opin Emerg Drugs. 2012;17(3):393–406.
   PubMed Web of Science ®Google Scholar
• Schuster MN , Vollbracht S , Rapoport AM . Emerging treatments for the primary headache disorders. Neurol Sci. 2015;36:109–113.
   PubMed Web of Science ®Google Scholar
• Goadbsy PJ , Lipton RB , Ferrari MD . Migraine - Current understanding and treatment. N Engl J Med. 2002;346(4):257–270.
   PubMed Web of Science ®Google Scholar
• Houston DS , Vanhoutte PM . Serotonin and the vascular system: role in health and disease, and implications for therapy. Drugs. 1986;31(2):149–163.
   PubMed Web of Science ®Google Scholar
• Durham PL , Russo AF . Regulation of calcitonin gene-related peptide secretion by a serotonergic antimigraine drug. J Neurosci. 1999;19(9):3423–3429.
   PubMed Web of Science ®Google Scholar
• Charles A . Defining and refining 5-HT receptor targets for migraine. Lancet Neurol. 2012;11(5):383–384.
   PubMed Web of Science ®Google Scholar
• Edvinsson L . The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. Headache. 2017;57:47–55.
   PubMed Web of Science ®Google Scholar
• Hostetler ED , Joshi AD , Sanabria-Bohórquez S , et al. In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232. J Pharmacol Exp Ther. 2013;347(2):478–486.
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen PC , Pihl T , Hougaard A , et al. Drugs targeting 5-hydroxytryptamine receptors in acute treatments of migraine attacks. A review of new drugs and new administration forms of established drugs. Expert opin investig Drugs. 2014;23(3):375–385.
   PubMed Web of Science ®Google Scholar
• Hougaard A , Tfelt-Hansen PC . Review of dose–response curves for acute antimigraine drugs: triptans, 5-HT 1F agonists and CGRP antagonists. Expert Opin Drug Metab Toxicol. 2015;5255:1–10.
   Google Scholar
• Orr SL , Friedman BW , Christie S , et al. Management of adults with acute migraine in the emergency department: the American Headache Society Evidence Assessment of Parenteral Pharmacotherapies. Headache. 2016;56(6):911–940.
   PubMed Web of Science ®Google Scholar